Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: Mar 11, 2025

-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --